Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in ...

In hormone receptor (HR)–positive, HER2-negative advanced breast cancer, starting CDK4/6 inhibitors (CDK4/6i) in the first line of therapy did not improve overall survival (OS) compared with reserving ...

Patients with advanced estrogen receptor (ER)-positive breast cancer that progressed on CDK4/6 inhibitors had better survival if they continued CDK4/6 inhibition plus endocrine therapy rather than ...

In a cohort study of nearly 16,000 US patients with breast cancer who were prescribed a cyclin-dependent kinase (CDK) 4/6 inhibitor, only 46% underwent liver function testing in the 2 weeks before ...

SAN ANTONIO — A machine learning model, which incorporates both clinical and genomic factors, helps predict which patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2 ...

A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR ...

Backed by $70m in Series A funding, Elevara Medicines has launched to advance its CDK4/6 inhibitor, which belongs to a drug class that has traditionally been used in breast cancer, as an add-on ...

Electronic patient reported outcomes in breast cancer patients receiving adjuvant chemotherapy with doxorubicin/cyclophosphamide combined with paclitaxel compared to ...

No significant OS advantage was found among CDK4/6 inhibitors for HR-positive, HER2-negative metastatic breast cancer. Real-world data showed median OS of 54.6 months for Ibrance, 59 months for ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, necessitating new therapeutic strategies. CDK4/6 inhibitors show promise ...